TABLE 1.
Clinical Characteristics of Anti-PD-1 First and BRAFi- First Cohorts
| Variables | n (%) |
|||
|---|---|---|---|---|
| Anti-PD-1 First (N = 56) |
BRAFi First (N = 58) |
P | ||
|
| ||||
| Age (median) (y) | 56.5 | 50 | 0.15 | |
| Sex | ||||
| Male | 37 (66) | 35 (60) | 0.66 | |
| Female | 19 (34) | 23 (40) | ||
| ECOG performance status | ||||
| 0 | 46 (82) | 40 (70) | 0.18 | |
| 1–2 | 10 (18) | 17 (30) | ||
| Brain metastases | ||||
| Yes | 5(9) | 14 (24) | 0.05 | |
| No | 51 (91) | 44 (76) | ||
| Lactate dehydrogenase | ||||
| Normal | 40 (74) | 27 (54) | 0.05 | |
| > ULN | 10 (19) | 20 (40) | ||
| >2xULN | 4(7) | 3(6) | ||
| Anti-PD-1 agent | ||||
| Nivolumab | 10 (18) | 8(14) | < 0.001 | |
| Pembrolizumab | 24 (43) | 45 (78) | ||
| Atezolizumab | 3(5) | 3 (5) | ||
| Ipilimumab + nivolumab | 19 (34) | 2 (3) | ||
| BRAF inhibitor | ||||
| BRAFi monotherapy | 13 (23) | 26 (45) | * | |
| BRAFi + MEKi | 9(16) | 32 (55) | ||
| None | 34 (61) | 0 | ||
| Prior therapy | ||||
| Prior ipilimumab | 12 (21) | 16 (28) | 0.86 | |
| Prior IL-2 | 12 (21) | 12 (21) | ||
| Prior chemotherapy | 3(5) | 4 (7) | ||
Baseline lactate dehydrogenase and ECOG performance status not documented in 10 and 1 patients, respectively.
*
Denotes no formal statistical testing performed.
ECOG indicates Eastern Cooperative Oncology Group; IL-2, interleukin-2; ULN, upper limit of normal.